Neural Noise

Neurotech and institutional initiatives for Alzheimer's disease (Cognito, WVU)

2 min read

  • Cognito is a neurotech company with initiatives aimed at a future beyond Alzheimer’s disease.1
  • West Virginia University (WVU) hosts an institutional neurotech initiative (Cognito collaboratory) relevant to Alzheimer’s and BCI/neurotechnology.1 1

Weekly enrichment (2026-07-20)

  • Cognito Therapeutics and West Virginia University’s Rockefeller Neuroscience Institute (RNI) announced a “Brain Health Collaboratory” partnership (November 2025), building a rural, neurotech-enabled learning healthcare system initially focused on Alzheimer’s disease and co-funded by both organizations.2
  • Cognito Therapeutics was founded in 2016 by neuroscientists Ed Boyden and Li-Huei Tsai and has raised over $200M in private capital; its Spectris headset delivers combined 40 Hz auditory and light (gamma) sensory stimulation for one hour per day at home.2
  • Spectris earned FDA Breakthrough Device designation (2020–2021), and Cognito’s pivotal HOPE trial (NCT05637801) is fully enrolled with roughly 670–673 patients, with study completion anticipated in spring 2026.234
  • HOPE is a randomized, double-blind, sham-controlled study (1:1 active:sham) across up to ~70 US clinical sites, using the device 60 minutes daily for approximately 12 months followed by a 12-month open-label extension, in mild-to-moderate AD (MMSE 15–28).34
  • The primary endpoint is the Integrated Alzheimer’s Disease MMSE + ADCS-ADL Rating Scale (iADMARS), a combined measure of cognition (MMSE) and daily function (ADCS-ADL) at 12 months.4
  • The earlier OVERTURE feasibility study (NCT03556280) reported a 76% reduction in cognitive decline (MMSE), a 77% reduction in functional decline (ADCS-ADL), and a 69% reduction in whole-brain atrophy over 6 months by MRI.35
  • RNI, described as an eight-year-old unit integrating neurology, neurosurgery, psychiatry, radiology, and rehab, cares for about 300,000 patients across a rural footprint (West Virginia, SW Pennsylvania, Eastern Ohio, Western Maryland), including roughly 10,000 Alzheimer’s and 9,000 Parkinson’s patients annually across 47 practice locations.2
  • RNI, led by neurosurgeon Ali Rezai, also pioneered focused-ultrasound blood-brain-barrier opening for Alzheimer’s: a first-in-human NEJM study paired MRI-guided focused ultrasound (an Insightec helmet with more than 1,000 transducers) with the anti-amyloid antibody aducanumab to accelerate amyloid-beta clearance (about 32% faster), with the barrier closing within 24–48 hours and no serious adverse events reported.67

Footnotes

  1. https://neurotechnology.substack.com/p/cognito-collaboratory ↩ ↩2 ↩3

  2. https://neurotechnology.substack.com/p/cognito-collaboratory ↩ ↩2 ↩3 ↩4

  3. https://www.businesswire.com/news/home/20250701375054/en/Cognito-Therapeutics-Completes-Enrollment-in-HOPE-Pivotal-Study-of-Spectris-AD-Therapy-for-the-Treatment-of-Patients-with-Alzheimers-Disease ↩ ↩2 ↩3

  4. https://clinicaltrials.gov/study/NCT05637801 ↩ ↩2 ↩3

  5. https://www.medicaleconomics.com/view/cognito-therapeutics-completes-enrollment-in-landmark-alzheimer-s-trial ↩

  6. https://wvumedicine.org/news/article/WVU-Medicine/Front-Page/breakthrough-in-treating-alzheimer-s-using-targeted-drug-delivery-reported-in-new-england-journal-of-medicine/ ↩

  7. https://www.nejm.org/doi/full/10.1056/NEJMoa2308719 ↩

Graph View